3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Sarcoma
19
Ovarian Neoplasms
7
Leiomyosarcoma
6
Liposarcoma
4
Liposarcoma, Myxoid
3
Sarcoma, Ewing
2
Osteosarcoma
2
Solitary Fibrous Tumors
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrence
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Epithelial Cancer Recurrent
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leiomyosarcoma Uterus
1
Ichthyosis, X-Linked
1
Histiocytoma, Malignant Fibrous
1
Hemangioendothelioma
1
Fanconi Anemia, Complementation Group D1
1
Chondrosarcoma
1
Carcinosarcoma
1
Cancers With DNA Repair-Deficiency
1
Bone Neoplasms
1
Interventions
Filgrastim
4
Proton Therapy
3
Docetaxel
3
regorafenib
2
Sunitinib
2
Ifosfamide
2
Gemcitabine
2
Carboplatin
2
temsirolimus
1
pegfilgrastim
1
liposomal doxorubicin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
ivosidenib
1
itacitinib
1
etoposide phosphate
1
capivasertib
1
baricitinib
1
apatinib
1
angiotensin I (1-7)
1
abemaciclib
1
Zoledronic Acid
1
Weight-Bearing
1
Trabectedin
1
Topotecan
1
Thiotepa
1
Thalidomide
1
Taxes
1
TQ-B3525
1
Surveys and Questionnaires
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Chondrosarcoma
×
Trabectedin
×
Clear all
NCT05131386
2023-03-27
SYNERGIAS
Grupo Espanol de Investigacion en Sarcomas
Phase 2
Unknown
85 enrolled